RxDoctor Payments Data

Aaron Pittard, MD

Ophthalmology · San Antonio, TXNPI 1013929728

Payments from drug & device makers

$868in general payments, 2019–2025

Across 21 payments — averaging $41.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$468
  • AbbVie$157
  • Alcon$104
  • Rxsight Inc$101
  • Omeros Corporation$21
  • Bausch & Lomb Americas Inc.$17

What the payments were for

  • Food & beverage$868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$868 in reported general payments places this provider in the 30th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$291,115
Medicare patients
1,069
Services billed
2,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost79$52,855
RestasisCyclosporine40$41,982
Prednisolone Acetate372$20,259
XiidraLifitegrast11$17,892
CombiganBrimonidine Tartrate/Timolol47$17,465
Travoprost83$11,999
RhopressaNetarsudil Mesylate12$11,365
Latanoprost992$10,935
MoxifloxacinMoxifloxacin Hcl366$10,688
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol79$10,182
Brimonidine Tartrate141$7,549
Alphagan PBrimonidine Tartrate19$6,804
Timolol Maleate210$4,927
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat388$4,500
Bromfenac Sodium11$1,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$157$119,105185 claims
Bausch & Lomb Americas Inc.Xiidra$17$17,89211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →